Onychomycosis Treatment Market Expansion Continues, with Forecast Valuation of $5.1 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Onychomycosis Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market valuation for onychomycosis remedies has experienced robust expansion lately, projected to increase from $3.65 billion in 2024 to reach $3.91 billion by 2025, reflecting a compound annual growth rate of 7.1%; this upward trajectory during the past period stems from several factors, notably the escalation in fungal infection incidents, an expanding elderly demographic, heightened public knowledge surrounding the condition, the increasing frequency of onychomycosis cases, and greater levels of available consumer spending power.

Onychomycosis Treatment Market Size Forecast: What's the Projected Valuation by 2029?
Anticipated for the coming years is a robust expansion within the domain of onychomycosis remedies, with projections indicating a market valuation reaching $5.1 billion by 2029, fueled by a compound annual growth rate (CAGR) of 6.9%; this upward trajectory over the predicted timeframe is underpinned by several factors, notably the aging global demographic, the broadening utilization of telemedicine, the integration of multifaceted treatment approaches, enhanced availability of medical services, shifts in daily habits alongside ecological influences, and a rising incidence of diabetes among populations, while key developments shaping this sector include progress in dermatological science, novel methods for drug administration, tailored treatment regimens, improvements in topical applications, the adoption of digital healthcare platforms, and the deployment of laser-based therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What Are the Drivers Transforming the Onychomycosis Treatment Market?
A rise is anticipated in the market centered on onychomycosis treatments, fueled by the expanding global incidence of fungal ailments; these microbial diseases stem from diverse fungi impacting various anatomical sites or leading to specific pathologies, and onychomycosis, specifically a fungal affliction of the nail, usually necessitates intervention via oral antifungals or topical antifungal formulations to eradicate the root cause of the fungal proliferation and facilitate the regeneration of the nail structure. As an illustration, data released in September 2023 by the UK Health Security Agency, a national governing body in the United Kingdom, indicated that 2,265 instances of bloodstream infections (BSI) attributed to yeast were documented across England during the year 2022 via the SGSS (Surveillance of Antimicrobial Resistance Service); furthermore, the collective rate of yeast-related BSI experienced a modest upward trend, reaching 4.0 per 100,000 inhabitants, an increment from the preceding year's figure of 3.8 per 100,000, with the trio of yeast species most frequently isolated from blood specimens comprising Candida albicans (accounting for 40%), Nakaseomyces glabratus (previously known as Candida glabrata, responsible for 29%), and Candida parapsilosis (at 13%), underscoring how the greater prevalence of fungal infections acts as a significant impetus for the expansion of the market for onychomycosis therapeutics.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

What Long-Term Trends Will Define the Future of the Onychomycosis Treatment Market?
Leading entities within the onychomycosis therapeutic space are prioritizing the innovation of novel treatments, exemplified by MOB-015, and seeking requisite endorsements from regulatory bodies to sharpen their market standing. As a case in point, Moberg Pharma AB, a pharmaceutical enterprise headquartered in Sweden, secured crucial authorization for MOB-015 within the European Union in June 2023, designating it for adult use in addressing mild to moderate nail fungal ailments. This European Union clearance represents the initial worldwide marketing endorsement achieved by this groundbreaking onychomycosis remedy. The underpinning for MOB-015's acceptance came from two Phase 3 studies, which illustrated superior performance, showing a mycological cure rate reaching 76% compared to rates as low as 42% for alternative treatments, alongside a markedly higher overall cure rate when contrasted with the placebo, all while presenting no instances of severe adverse reactions. MOB-015, which functions as a topical terbinafine preparation, facilitates adequate penetration of the active drug to the affected nail and nail bed areas, thereby circumventing the systemic exposure risks inherent in administering oral terbinafine medications.

Which Segments in the Onychomycosis Treatment Market Offer the Most Profit Potential?
The onychomycosis treatmentmarket covered in this report is segmented -

1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types
2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy
3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

Which Firms Dominate the Onychomycosis Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

Which Regions Offer the Highest Growth Potential in the Onychomycosis Treatment Market?
North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.